Nevro And Medtronic Announce FDA Approval Of Spinal Cord Stimulation Label Expansions
Executive Summary
The FDA approved a diabetic peripheral neuropathy indication for Medtronic’s Intellis and Vanta spinal cord stimulators a few days after expanding the indication for Senza Nevro’s spinal cord stimulation system to include non-surgical refractory back pain.
You may also be interested in...
Exec Chat: Medtronic Neuromodulation Approaches Inflection Point
Medtech Insight talked to Ashwini Sharan, the new chief medical officer for Medtronic's neuromodulation business, and and Nnamdi Njoku, the president of the business, to learn about the company's vision for neuromodulation technology and how the company can leverage its particular strengths make these therapies more effective and accessible.
Minute Insight: Nevro Secures Coverage For HFX Pain Therapy From Largest US Insurance Company
UnitedHealthcare will provide coverage for Nevro’s HFX spinal cord stimulation therapy for the treatment of painful diabetic neuropathy beginning on 1 March. Analysts believe the decision bodes well for the company’s chances of securing coverage from other insurers.
Nevro Turns To Clinical Evidence To Attract Doctors, Patients And Reimbursement For Pain Therapy
The FDA recently approved Nevro’s Senza high-frequency spinal cord stimulation systems to treat pain caused by diabetic neuropathy. Now it plans to expand its proprietary HFX high-frequency treatment to more indications.